Edward McDonald
Overview
Explore the profile of Edward McDonald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlechter J, Pak T, Gornick B, McDonald E
Orthop J Sports Med
. 2022 Aug;
10(8):23259671221114629.
PMID: 35935342
Background: Failure to address meniscus root tears may place undue loads on anterior cruciate ligament (ACL) reconstructive surgery in the adult population. Because the intraoperative management of lateral meniscus posterior...
2.
Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, et al.
PLoS One
. 2020 Jul;
15(7):e0234103.
PMID: 32645016
Cyclin-dependent kinases (CDKs) contribute to the cancer hallmarks of uncontrolled proliferation and increased survival. As a result, over the last two decades substantial efforts have been directed towards identification and...
3.
Sharp S, Boxall K, Rowlands M, Prodromou C, Roe S, Maloney A, et al.
Cancer Res
. 2019 Jan;
79(1):287.
PMID: 30602624
No abstract available.
4.
Whittaker S, Barlow C, Martin M, Mancusi C, Wagner S, Self A, et al.
Mol Oncol
. 2017 Oct;
12(3):287-304.
PMID: 29063678
Deregulation of the cyclin-dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types. Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer....
5.
Stockwell S, Platt G, Barrie S, Zoumpoulidou G, Te Poele R, Aherne G, et al.
PLoS One
. 2012 Jan;
7(1):e28568.
PMID: 22253692
Human cancers often contain genetic alterations that disable G1/S checkpoint control and loss of this checkpoint is thought to critically contribute to cancer generation by permitting inappropriate proliferation and distorting...
6.
Wilson S, Atrash B, Barlow C, Eccles S, Fischer P, Hayes A, et al.
Bioorg Med Chem
. 2011 Oct;
19(22):6949-65.
PMID: 21982796
The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility,...
7.
Large J, Torr J, Raynaud F, Clarke P, Hayes A, Stefano F, et al.
Bioorg Med Chem
. 2011 Jan;
19(2):836-51.
PMID: 21216151
Two classes of trisubstituted pyrimidines related to PI-103 1 have been prepared and their inhibitory activities against phosphatidylinositol 3-kinase (PI3K) p110α were determined. From those with direct 6-aryl substitution compound...
8.
Bouloc N, Large J, Kosmopoulou M, Sun C, Faisal A, Matteucci M, et al.
Bioorg Med Chem Lett
. 2010 Sep;
20(20):5988-93.
PMID: 20833547
Co-crystallisation of the imidazo[1,2-a]pyrazine derivative 15 (3-chloro-N-(4-morpholinophenyl)-6-(pyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine) with Aurora-A provided an insight into the interactions of this class of compound with Aurora kinases. This led to the design and synthesis...
9.
Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, et al.
Cancer Res
. 2010 Jul;
70(14):5963-73.
PMID: 20610623
The Wnt signaling pathway is frequently deregulated in cancer due to mutations in genes encoding APC, beta-catenin, and axin. To identify small-molecule inhibitors of Wnt signaling as potential therapeutics, a...
10.
Bavetsias V, Large J, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, et al.
J Med Chem
. 2010 Jun;
53(14):5213-28.
PMID: 20565112
Lead optimization studies using 7 as the starting point led to a new class of imidazo[4,5-b]pyridine-based inhibitors of Aurora kinases that possessed the 1-benzylpiperazinyl motif at the 7-position, and displayed...